|
1
|
Mao XG, Zhang X and Zhen HN: Progress on
potential strategies to target brain tumor stem cells. Cell Mol
Neurobiol. 29:141–155. 2009. View Article : Google Scholar
|
|
2
|
Maher EA, Furnari FB, Bachoo RM, Rowitch
DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics
and biology of a grave matter. Genes Dev. 15:1311–1333. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanai N and Berger MS: Glioma extent of
resection and its impact on patient outcome. Neurosurgery.
62:753–764; discussion 264–266. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bexell D, Gunnarsson S, Tormin A, Darabi
A, Gisselsson D, Roybon L, Scheding S and Bengzon J: Bone marrow
multipotent mesenchymal stroma cells act as pericyte-like migratory
vehicles in experimental gliomas. Mol Ther. 17:183–190. 2009.
View Article : Google Scholar
|
|
5
|
Gunnarsson S, Bexell D, Svensson A, Siesjö
P, Darabi A and Bengzon J: Intratumoral IL-7 delivery by
mesenchymal stromal cells potentiates IFNgamma-transduced tumor
cell immuno-therapy of experimental glioma. J Neuroimmunol.
218:140–144. 2010. View Article : Google Scholar
|
|
6
|
Matuskova M, Hlubinova K, Pastorakova A,
Hunakova L, Altanerova V, Altaner C and Kucerova L: HSV-tk
expressing mesenchymal stem cells exert bystander effect on human
glio-blastoma cells. Cancer Lett. 290:58–67. 2010. View Article : Google Scholar
|
|
7
|
Suryadevara CM, Verla T, Sanchez-Perez L,
Reap EA, Choi BD, Fecci PE and Sampson JH: Immunotherapy for
malignant glioma. Surg Neurol Int. 6(Suppl 1): S68–S77. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okamura H, Tsutsi H, Komatsu T, Yutsudo M,
Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et
al: Cloning of a new cytokine that induces IFN-gamma production by
T cells. Nature. 378:88–91. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hwang KS, Cho WK, Yoo J, Seong YR, Kim BK,
Kim S and Im DS: Adenovirus-mediated interleukin-18 mutant in vivo
gene transfer inhibits tumor growth through the induction of T cell
immunity and activation of natural killer cell cytotoxicity. Cancer
Gene Ther. 11:397–407. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ossendorp F, Mengedé E, Camps M, Filius R
and Melief CJ: Specific T helper cell requirement for optimal
induction of cytotoxic T lymphocytes against major
histocompatibility complex class II negative tumors. J Exp Med.
187:693–702. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kohyama M, Saijyo K, Hayasida M, Yasugi T,
Kurimoto M and Ohno T: Direct activation of human CD8+
cytotoxic T lymphocytes by interleukin-18. Jpn J Cancer Res.
89:1041–1046. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xia D, Li F and Xiang J: Engineered fusion
hybrid vaccine of IL-18 gene-modified tumor cells and dendritic
cells induces enhanced antitumor immunity. Cancer Biother
Radiopharm. 19:322–330. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Glick RP, Lichtor T, Mogharbel A, Taylor
CA and Cohen EP: Intracerebral versus subcutaneous immunization
with allogeneic fibroblasts genetically engineered to secrete
interleukin-2 in the treatment of central nervous system glioma and
melanoma. Neurosurgery. 41:898–906; discussion 906–907. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sobol RE, Fakhrai H, Shawler D, Gjerset R,
Dorigo O, Carson C, Khaleghi T, Koziol J, Shiftan TA and Royston I:
Interleukin-2 gene therapy in a patient with glioblastoma. Gene
Ther. 2:164–167. 1995.PubMed/NCBI
|
|
15
|
Hertzog PJ, Hwang SY and Kola I: Role of
interferons in the regulation of cell proliferation,
differentiation, and development. Mol Reprod Dev. 39:226–232. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakahara N, Pollack IF, Storkus WJ,
Wakabayashi T, Yoshida J and Okada H: Effective induction of
antiglioma cytotoxic T cells by coadministration of interferon-beta
gene vector and dendritic cells. Cancer Gene Ther. 10:549–558.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Williams RF, Myers AL, Sims TL, Ng CY,
Nathwani AC and Davidoff AM: Targeting multiple angiogenic pathways
for the treatment of neuroblastoma. J Pediatr Surg. 45:1103–1109.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kageshita T, Mizuno M, Ono T, Matsumoto K,
Saida T and Yoshida J: Growth inhibition of human malignant
melanoma transfected with the human interferon-beta gene by means
of cationic liposomes. Melanoma Res. 11:337–342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Natsume A, Mizuno M, Ryuke Y and Yoshida
J: Antitumor effect and cellular immunity activation by murine
interferon-beta gene transfer against intracerebral glioma in
mouse. Gene Ther. 6:1626–1633. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Natsume A, Tsujimura K, Mizuno M,
Takahashi T and Yoshida J: IFN-beta gene therapy induces systemic
antitumor immunity against malignant glioma. J Neurooncol.
47:117–124. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu G, Jiang XD, Xu Y, Zhang J, Huang FH,
Chen ZZ, Zhou DX, Shang JH, Zou YX and Cai YQ: Adenoviral-mediated
interleukin-18 expression in mesenchymal stem cells effectively
suppresses the growth of glioma in rats. Cell Biol Int. 33:466–474.
2009. View Article : Google Scholar
|
|
22
|
Olson JJ, Friedman R, Orr K, Delaney T and
Oldfield EH: Enhancement of the efficacy of x-irradiation by
pentobarbital in a rodent brain-tumor model. J Neurosurg.
72:745–748. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Farrell CL, Stewart PA and Del Maestro RF:
A new glioma model in rat: The C6 spheroid implantation technique
permeability and vascular characterization. J Neurooncol.
4:403–415. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen W, Wang J, Shao C, Liu S, Yu Y, Wang
Q and Cao X: Efficient induction of antitumor T cell immunity by
exosomes derived from heat-shocked lymphoma cells. Eur J Immunol.
36:1598–1607. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lohr J, Ratliff T, Huppertz A, Ge Y,
Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, et al:
Effector T-cell infiltration positively impacts survival of
glioblastoma patients and is impaired by tumor-derived TGF-β. Clin
Cancer Res. 17:4296–4308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kraman M, Bambrough PJ, Arnold JN, Roberts
EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT:
Suppression of antitumor immunity by stromal cells expressing
fibroblast activation protein-alpha. Science. 330:827–830. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamizo A, Marini F, Amano T, Khan A,
Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et
al: Human bone marrow-derived mesenchymal stem cells in the
treatment of gliomas. Cancer Res. 65:3307–3318. 2005.PubMed/NCBI
|
|
28
|
Uchibori R, Okada T, Ito T, Urabe M,
Mizukami H, Kume A and Ozawa K: Retroviral vector-producing
mesenchymal stem cells for targeted suicide cancer gene therapy. J
Gene Med. 11:373–381. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Menon LG, Kelly K, Yang HW, Kim SK, Black
PM and Carroll RS: Human bone marrow-derived mesenchymal stromal
cells expressing S-TRAIL as a cellular delivery vehicle for human
glioma therapy. Stem Cells. 27:2320–2330. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao
G, Huang M, Cheng LH, Dai LJ and Zhang L: TRAIL-engineered bone
marrow-derived mesenchymal stem cells: TRAIL expression and
cytotoxic effects on C6 glioma cells. Anticancer Res. 34:729–734.
2014.PubMed/NCBI
|
|
31
|
Liu W, Han B, Sun B, Gao Y, Huang Y and Hu
M: Overexpression of interleukin-18 induces growth inhibition,
apoptosis and gene expression changes in a human tongue squamous
cell carcinoma cell line. J Int Med Res. 40:537–544. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu W, Hu M, Wang Y, Sun B, Guo Y, Xu Z,
Li J and Han B: Overexpression of interleukin-18 protein reduces
viability and induces apoptosis of tongue squamous cell carcinoma
cells by activation of glycogen synthase kinase-3β signaling. Oncol
Rep. 33:1049–1056. 2015.PubMed/NCBI
|
|
33
|
Zheng JN, Pei DS, Mao LJ, Liu XY, Sun FH,
Zhang BF, Liu YQ, Liu JJ, Li W and Han D: Oncolytic adenovirus
expressing interleukin-18 induces significant antitumor effects
against melanoma in mice through inhibition of angiogenesis. Cancer
Gene Ther. 17:28–36. 2010. View Article : Google Scholar
|
|
34
|
Takano S, Ishikawa E, Matsuda M, Yamamoto
T and Matsumura A: Interferon-β inhibits glioma angiogenesis
through downregulation of vascular endothelial growth factor and
upregulation of interferon inducible protein 10. Int J Oncol.
45:1837–1846. 2014.PubMed/NCBI
|
|
35
|
Yoshida J, Mizuno M and Yagi K:
Cytotoxicity of human beta-interferon produced in human glioma
cells transfected with its gene by means of liposomes. Biochem Int.
28:1055–1061. 1992.PubMed/NCBI
|
|
36
|
Guo Y, Wang G, Gao WW, Cheng SW, Wang R,
Ju SM, Cao HL and Tian HL: Induction of apoptosis in glioma cells
and upregulation of Fas expression using the human interferon-β
gene. Asian Pac J Cancer Prev. 13:2837–2840. 2012. View Article : Google Scholar
|
|
37
|
Zhang Y, Wang C, Zhang Y and Sun M: C6
glioma cells retrovi-rally engineered to express IL-18 and Fas
exert FasL-dependent cytotoxicity against glioma formation. Biochem
Biophys Res Commun. 325:1240–1245. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marshall DJ, Rudnick KA, McCarthy SG,
Mateo LR, Harris MC, McCauley C and Snyder LA: Interleukin-18
enhances Th1 immunity and tumor protection of a DNA vaccine.
Vaccine. 24:244–253. 2006. View Article : Google Scholar
|
|
39
|
Robertson MJ, Mier JW, Logan T, Atkins M,
Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, et al:
Clinical and biological effects of recombinant human interleukin-18
administered by intravenous infusion to patients with advanced
cancer. Clin Cancer Res. 12:4265–4273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kikuchi T, Akasaki Y, Joki T, Abe T,
Kurimoto M and Ohno T: Antitumor activity of interleukin-18 on
mouse glioma cells. J Immunother. 23:184–189. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yamanaka R and Xanthopoulos KG: Induction
of antigen-specific immune responses against malignant brain tumors
by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
DNA Cell Biol. 24:317–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yamanaka R, Honma J, Tsuchiya N, Yajima N,
Kobayashi T and Tanaka R: Tumor lysate and IL-18 loaded dendritic
cells elicits Th1 response, tumor-specific CD8+
cytotoxic T cells in patients with malignant glioma. J Neurooncol.
72:107–113. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yamanaka R, Tsuchiya N, Yajima N, Honma J,
Hasegawa H, Tanaka R, Ramsey J, Blaese RM and Xanthopoulos KG:
Induction of an antitumor immunological response by an intratumoral
injection of dendritic cells pulsed with genetically engineered
Semliki Forest virus to produce interleukin-18 combined with the
systemic administration of interleukin-12. J Neurosurg. 99:746–753.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Meijer DH, Maguire CA, LeRoy SG and
Sena-Esteves M: Controlling brain tumor growth by intraventricular
administration of an AAV vector encoding IFN-beta. Cancer Gene
Ther. 16:664–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Streck CJ, Dickson PV, Ng CY, Zhou J, Hall
MM, Gray JT, Nathwani AC and Davidoff AM: Antitumor efficacy of
AAV-mediated systemic delivery of interferon-beta. Cancer Gene
Ther. 13:99–106. 2006. View Article : Google Scholar
|
